Healthcare >> CEO Interviews >> August 6, 2001
WILLIAM A. CARTER, MD, the co-inventor of Ampligen, joined
HemispherX BioPharma in 1978, and has served as the company's
Chief Scientific Officer since May 1989, the Chairman of the
company's Board of Directors since January 1992, the company's
Chief Executive Office since July 1993, the company's President
since April 1995, and a Director since 1987. From 1987 to 1988,
Dr. Carter served as the company's Chairman. Dr. Carter was a
leading innovator in the development of human interferon for a
variety of treatment indications including various viral diseases
and cancer. In this context, he received the first FDA approval
to initiate clinical trials on a beta interferon product
manufactured in the US under his supervision. Dr. Carter's work
with interferon, now widely used in clinical medicine, was
pioneered during his tenure at Johns Hopkins University and the
National Institutes of Health. Dr. Carter was a pioneer in the
clinical development of interferon and developed the first US-
based manufacturing facility for beta interferon. From 1985 to
October 1988, Dr. Carter served as the company's Chief Executive
Officer and Chief Scientist. He received his MD degree from Duke
University and underwent his post-doctoral training at the
National Institutes of Health and Johns Hopkins University. Dr.
Carter also serves as Professor of Neoplastic Diseases at
Allegheny University, a position he has held since 1980. He is
also Director of Clinical Research at Allegheny University's
Institute for Cancer and Blood diseases. Dr. Carter has served as
a professor at Johns Hopkins School of Medicine, Allegheny
University, and the State University of New York at Buffalo. Profile
Dr. Carter: The company was founded actually as a NIH support company
about 25 to 30 years ago. It did some of the early
